arrow
F

Francesco Deodato

centro nazionale di adroterapia oncologica
H指数:33
被引数:3,897

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Defining Intraprostatic Gross Tumor Volume and Micro-boosting through Consensus: A Contour-Based Modified Delphi Consensus

通过共识定义前列腺内大体肿瘤体积和微增量:一种基于轮廓的改良德尔菲共识

2026-07-290
PRE
Older Age Does Not Predict Inadequate Pain Management in Cancer Patients: A Multicenter Prospective Analysis from Italian Radiotherapy Departments (ARISE-Study)

老年并非预示癌症患者疼痛管理不足:一项来自意大利放疗科的多中心前瞻性分析(ARISE研究)

Cancers
IF4.4
2026-03-030
OA
REASSESSING THE RISKS: TOXICITY PROFILE OF STEREOTACTIC ABLATIVE RADIOTHERAPY AFTER BEVACIZUMAB IN OLIGOMETASTATIC OVARIAN CANCER – A NEW PERSPECTIVE FOR RADIATION ONCOLOGISTS?

重新评估风险:在寡转移性卵巢癌中,经贝伐珠单抗治疗后立体定向消融放射治疗的毒性特征——这对放射肿瘤学家而言是否是一种新的视角?

2025-12-160
OA
Impact of whole-brain radiation therapy on neurocognitive functions, alopecia and hearing loss: a systematic review and meta-analysis endorsed by the Palliative Care and Neuro-Oncology Study Groups of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

全脑放射治疗对神经认知功能、脱发和听力损失的影响:一项由意大利放射治疗与临床肿瘤学会(AIRO)姑息治疗与神经肿瘤学研究组支持的系统评价和Meta分析

2025-11-080
PRE
Plasma branched-chain amino acids and risk of radiation-induced acute skin toxicity in women with breast cancer: results from the ATHENA project

血浆支链氨基酸与放疗诱导的急性皮肤毒性的风险:ATHENA项目的结果

2025-10-200
OAAI
Treatment of Oligometastatic Parenchymal Lesions in Ovarian Cancer With Stereotactic Ablative Radiation Therapy: A Multicenter Prospective Phase 2 Trial (MITO RT3/RAD)

治疗卵巢癌寡转移性实质病灶的立体定向消融放射疗法:一项多中心前瞻性II期试验(MITO RT3/RAD)

2025-03-310
PRE
Accelerated Relief: A Narrative Review of Two-Daily Fractions Palliative Radiotherapy in Advanced Cancer Care

加速缓解:每日两次分割的姑息性放射疗法在晚期癌症护理中的叙事性综述

2025-03-210
OA
Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial
2025-03-010
PRE
Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study
2025-02-010
PRE